News

The trial will be conducted at Massachusetts General Hospital (MGH), the University of Massachusetts (UMass) Hospital and the Mayo Clinic. Dana-Farber’s Connell and O’Reilly Cell Manipulation Core plant

Tykerb in combination with capecitabine is indicated to treat advanced or metastatic breast cancer patients whose tumors overexpress HER2 and who were previously treated with anthracycline, a taxane

The new North America Headquarters accomodates company’s generics, biologics, PSAI and proprietary product businesses in addition to the corporate support functions within North America. Dr. Reddy’s chairman and

The technology leverages immunotherapeutic IgE to develop treatment for cancer patients expressing the tumor-associated antigen PSA that is coupled with prostate cancer. The anti-PSA monoclonal IgE demonstrated ability

At present, Priligy is being marketed for premature ejaculation in 16 countries in Europe, Asia and Latin America and approved for the same indication in 56 countries across

Green tea will be added to the list of ingredients to enhance the weight loss. The ingredients of Acai Ultrazax Acai Diet Supplement are useful in maintaining the

The core technology of TissueGen includes patented processes for extrusion of biodegradable drug-loaded fibers at room temperature. The company’s patented extrusion process at room temperature enables delivery of

The multicenter, open label trial will compare SPI-2012’s effectiveness relative to a fixed and standard dose of pegfilgrastim as a simultaneous active control to each dose of SPI-2012.

The drug-device combination will leverage the Sensile SenseCore technology in a wearable minipump, which delivers the drug product under the skin using a very small needle. As part